Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (NCT05800951) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock
United States124 participantsStarted 2022-07-22
Plain-language summary
The CERAMICS study is designed to more clearly delineate the current care of acute myocardial infarction with cardiogenic shock (AMICS) patients who are treated with mechanical circulatory support (MCS) devices in the United States with significant experience in MCS, all of whom have the capability of MCS escalation on-site. Study enrollment is targeted at 120 patients at 20 hospital sites, evaluating clinical outcomes, and focusing on outcomes MCS escalation decision making and ICU level management.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis of acute AMI confirmed by a medical professional, with changes in serum biomarkers or evidence of ischemic EKG changes (STEMI or NSTEMI).
✓. Cardiogenic Shock present as defined by the presence of 2 OR MORE of the following criteria prior to PCI:
✓. Patient underwent PCI within 12 hours of hospital presentation.
Exclusion criteria
✕. Evidence of Anoxic Brain Injury
✕. Unwitnessed out of hospital cardiac arrest or any cardiac arrest in which return of spontaneous circulation (ROSC) is not achieved within 30 minutes
✕. IABP placed prior to MCS
✕. Septic, anaphylactic, hemorrhagic, and neurologic causes of shock